SCHEMBL675010

SCHEMBL675010

CCCCCc1cc(N)c2c(n1)[nH]c1ccc(C=Cc3ccc(OC)cc3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 2/20 0.43
HRH2 P25021 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
EGFR P00533 3/20 0.39
GHSR Q92847 1/20 0.39
MAOA P21397 1/20 0.39
ACHE P22303 1/20 0.39
MAOB P27338 1/20 0.39
BACE1 P56817 1/20 0.39
AHR P35869 1/20 0.37
MCHR1 Q99705 2/20 0.37
TUBB3 Q13509 3/20 0.37
ABCB1 P08183 2/20 0.37
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
TUBB4A P04350 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676276 0.89 MCHR1 (0.41) ALKEGFRMCHR1KDR
SCHEMBL676481 0.88 HRH2 (0.49) ALKHRH2HRH3EGFRGHSR
SCHEMBL3725135 0.84 GHSR (0.42) ALKHRH2HRH3GHSRAHR
SCHEMBL3725133 0.84 GHSR (0.42) ALKHRH2HRH3GHSRAHR
SCHEMBL677054 0.81 GHSR (0.40) ALKHRH2HRH3EGFRGHSR
SCHEMBL675670 0.79 GHSR (0.40) ALKGHSRAHRCCNB2CDK1
SCHEMBL3728347 0.79 ALK (0.52) ALKEGFRGHSRAHRCCNB2
SCHEMBL3728344 0.79 ALK (0.52) ALKEGFRGHSRAHRCCNB2
SCHEMBL675669 0.76 ALK (0.38) ALKEGFRGHSRAHRTUBB3
SCHEMBL675732 0.76 KDM4E (0.43) ALKEGFRMCHR1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 ALK 1/4885HRH2 1972/4885HRH3 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.